adagrasib
mirati
['adagrasib', 'nsclc', 'krystal-1', 'sclc', 'mirati']
 2022 updates: announced data from the phase ii krystal-1 study (cohort a) evaluating adagrasib 600 mg bid in #nsclc patients having the kras g12c mutation who have received at least one prior systemic therapy. learn more: #asc0 #asco2022 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry